Breaking News

GSK To Acquire Domantis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline (GSK) has entered an agreement to acquire Domantis Ltd., an antibody therapy developer, for $451 million in cash. The acquisition expands GSK’s biopharmaceuticals portfolio of antibody technology. Domantis, a privately-held British company, will become part of GSK’s Biopharmaceuticals Centre of Excellence for Drug Discovery (CEDD) but will continue to operate from its labs in Cambridge. Domantis’ current research programs include antibody therapies for rheu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters